Immix Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Immix Biopharma
IMMX Stock  USD 5.23  0.05  0.95%   
Immix Biopharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immix Biopharma's valuation are provided below:
Market Capitalization
275.6 M
Earnings Share
(0.77)
We have found one hundred twenty available fundamental trends for Immix Biopharma, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immix Biopharma regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 33.6 M in 2026. Enterprise Value is likely to drop to about 24.8 M in 2026
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 49.6 K, Net Interest Income of 1.2 M or Depreciation And Amortization of 139.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.44. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
  
Build AI portfolio with Immix Stock
Check out the analysis of Immix Biopharma Correlation against competitors.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Immix Biopharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets14.2 M26.4 M7.4 M
Slightly volatile
Short and Long Term Debt Total1.9 M967.3 K3 M
Slightly volatile
Other Current Liabilities3.9 M3.7 M1 M
Slightly volatile
Total Current Liabilities10.5 M10 M5 M
Slightly volatile
Property Plant And Equipment Net3.3 M3.1 M548.7 K
Slightly volatile
Accounts Payable6.5 M6.2 M1.3 M
Slightly volatile
Cash12.4 M20.3 M6.3 M
Slightly volatile
Non Current Assets Total3.3 M3.2 M558.3 K
Slightly volatile
Cash And Short Term Investments12.4 M20.3 M6.3 M
Slightly volatile
Net Receivables2.4 M2.3 M586.3 K
Slightly volatile
Common Stock Shares Outstanding34.2 M32.5 M10.1 M
Slightly volatile
Liabilities And Stockholders Equity14.2 M26.4 M7.4 M
Slightly volatile
Other Current Assets624.5 K622.7 K286.2 K
Slightly volatile
Other Stockholder Equity106.6 M101.5 M27.7 M
Slightly volatile
Total Liabilities11.7 M11.2 M5.3 M
Slightly volatile
Property Plant And Equipment Gross3.4 M3.2 M558.1 K
Slightly volatile
Short and Long Term Debt42.8 K45 K2.7 M
Slightly volatile
Total Current Assets13.7 M23.2 M7 M
Slightly volatile
Capital Stock3.3 K3.2 K1 K
Slightly volatile
Short Term Debt55.8 K58.7 K2.7 M
Slightly volatile
Common Stock3.3 K3.2 K1 K
Slightly volatile
Property Plant Equipment5.3 K3.2 K7.6 K
Slightly volatile
Current Deferred Revenue274.3 K308.6 K336.8 K
Slightly volatile
Other Liabilities380 K427.5 K466.6 K
Slightly volatile

Immix Biopharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision49.6 K47.2 K23.6 K
Slightly volatile
Depreciation And Amortization139.3 K132.7 K24.2 K
Slightly volatile
Selling General Administrative13.7 M13.1 M3.2 M
Slightly volatile
Other Operating Expenses27.4 M26.1 M6.5 M
Slightly volatile
Research Development13.6 M13 M3.4 M
Slightly volatile
Cost Of Revenue139.3 K132.7 K24.2 K
Slightly volatile
Total Operating Expenses27.4 M26.1 M6.5 M
Slightly volatile
Reconciled Depreciation139.3 K132.7 K24 K
Slightly volatile
Income Tax Expense49.6 K47.2 K23.7 K
Slightly volatile
Selling And Marketing Expenses5.2 K5.8 K6.3 K
Slightly volatile

Immix Biopharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow21.1 M20.1 M5.6 M
Slightly volatile
Depreciation139.3 K132.7 K24.2 K
Slightly volatile
Total Cash From Financing Activities13.5 M18.3 M6.7 M
Slightly volatile
End Period Cash Flow12.4 M20.3 M6.3 M
Slightly volatile
Change To Netincome681.8 K717.7 K1.9 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation9.649.196.821
Pretty Stable
Payables Turnover0.00540.00830.0061
Slightly volatile
Cash Per Share0.570.560.4317
Slightly volatile
Days Payables Outstanding67.8 K45.6 K67.5 K
Slightly volatile
Income Quality0.470.610.7012
Slightly volatile
Current Ratio2.542.676.8648
Pretty Stable
Capex Per Share0.03930.03750.0086
Slightly volatile
Average Receivables1.5 M1.4 M463.4 K
Slightly volatile
Interest Debt Per Share0.04150.04370.7761
Slightly volatile
Debt To Assets0.05120.05393.0193
Slightly volatile
Days Of Payables Outstanding67.8 K45.6 K67.5 K
Slightly volatile
Ebt Per Ebit1.041.12.1696
Pretty Stable
Quick Ratio2.542.676.8648
Pretty Stable
Net Income Per E B T1.11.151.0277
Slightly volatile
Cash Ratio2.222.346.5211
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.820.970.9984
Slightly volatile
Debt Ratio0.05120.05393.0193
Slightly volatile

Immix Biopharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap33.6 M56 M35.6 M
Slightly volatile
Enterprise Value24.8 M41.1 M32.8 M
Pretty Stable

Immix Fundamental Market Drivers

Immix Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immix Biopharma Financial Statements

Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue308.6 K274.3 K
Cost Of Revenue132.7 K139.3 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY